Entera Bio (ENTX) EBT Margin (2019 - 2025)

Entera Bio's (ENTX) quarterly EBT Margin came in at 6235.71% in Q1 2025, down 118.14% on a QoQ basis from 2858.54% in Q4 2024.

Entera Bio (ENTX) EBT Margin (2019 - 2025) Analysis & Trends

Entera Bio (ENTX) has 6 years of EBT Margin data on file, last reported at 6235.71% in Q1 2025.

Quarterly EBT Margin changed N/A year-over-year to 6235.71% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 28383.33% (down 2293471.0% YoY) and the FY2025 annual result came in at 27235.71%, down 2197218.0% from the prior year.
EBT Margin retreated to 6235.71% in Q1 2025, from 2858.54% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 1471.34% in Q1 2021 to a low of 35912.5% in Q3 2022.
A 4-year average of 8329.29% and a median of 4923.46% in 2022 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2021 — EBT Margin surged 375480 bps — and 2022, when it tumbled 3360750 bps.
Tracing ENTX's EBT Margin over 4 years: stood at 2493.94% in 2021, then slumped by 782 bps to 22007.14% in 2022, then soared by 87 bps to 2858.54% in 2024, then sank by 118 bps to 6235.71% in 2025.
The last three EBT Margin figures came in at 6235.71% (Q1 2025), 2858.54% (Q4 2024), and 7192.86% (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	138.75 Bn	130.90 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.96 Bn	77.96 Bn	3.93 Bn	35.61%
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn	35.71%
4	Moderna	56.33 Bn	51.19 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.56 Bn	28.25 Bn	992.69 Mn	13.77%
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	-25.06%
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.32 Bn	26.49 Bn	-	12.09%
10	Entera Bio	164.09 Mn	152.78 Mn	-	-

Download Data